A virtual event associated with the Society for Neuroscience Global Connectome
3:30 - 4:30 PM ET
REGISTRATION - Registration is open to the public and is not contingent upon registration for the SfN Global Connectome Meeting.
The objectives of this social are to inform the community about (1) what is known about the effects of SARS-CoV-2 on the nervous system, (2) the effects of COVID-19 on those suffering from mental, neurological, or substance use disorders, and (3) relevant NIH resources/funding opportunities focused on these effects. The format will include a panel with NIH Institute Directors and other leaders and a Q&A with attendees.
- 10 min: Setting the stage: The science and effects of SARS-CoV-2/COVID-19 on the nervous system
- Walter Koroshetz, MD, Director, National Institute of Neurological Disorders and Stroke (NINDS)
- Nora Volkow, MD, Director, National Institute on Drug Abuse (NIDA)
- 20 min: Roundtable with NIH Leadership on Institute interests and resources to address SARS-CoV-2 and the pandemic
- Helene Langevin, MD, National Center for Complementary and Integrative Health (NCCIH)
- George Koob, PhD, Director, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Eliezer Masliah, MD, Director, Division of Neuroscience, National Institute on Aging (NIA)
- Alison Cernich, PhD, Deputy Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Susan Sullivan, PhD, Program Director, National Institute on Deafness and Other Communication Disorders (NIDCD)
- Yolanda Vallejo, PhD, Program Director, National Institute of Dental and Craniofacial Research (NIDCR)
- Susan Borja, PhD, Program Chief, National Institute of Mental Health (NIMH)
- 30 min: Open discussion/Q&A with panel
- Questions can be sent beforehand to NeuroCOVIDQandA@nih.gov or typed directly in the chat box during the event.
As the COVID-19 pandemic continues, many in the neuroscience community are considering the effects of the virus and the pandemic on the nervous system and/or those with mental health, substance use, or neurological disorders. Perspectives from NIH Leadership on cutting-edge discoveries about SARS-CoV-2, scientific priorities, and available research resources, coupled with the opportunity for questions and community insights, will spur scientific enterprise to public benefit.